Cytomegalovirus and other herpesviruses after hematopoietic
cell and solid organ transplantation: From antiviral drugs to
virus-specific T cells

J 2022

Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ, Irena KOUTNÁ et. al.

Základní údaje

Originální název

Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells

Autoři

ŤAPUCHOVÁ, Ivana (703 Slovensko, domácí), Robert PYTLIK (203 Česká republika), Pavel ŠIMARA (203 Česká republika, domácí), Lenka TESAŘOVÁ (203 Česká republika, domácí) a Irena KOUTNÁ (203 Česká republika, garant, domácí)

Vydání

Transplant Immunology, Amsterdam, Elsevier B.V. 2022, 0966-3274

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30102 Immunology

Stát vydavatele

Nizozemské království

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 1.500

Kód RIV

RIV/00216224:14110/22:00125593

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.trim.2022.101539

UT WoS

000746028600010

Klíčová slova anglicky

Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy

Štítky

14110517, podil, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2023 12:20, Mgr. Tereza Miškechová

Anotace

V originále

Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.

Návaznosti

LM2018133, projekt VaV

Název: Český národní uzel Evropské infrastruktury pro translační medicínu (Akronym: EATRIS-ERIC-CZ)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Involvement of Czech Translational Medicine Infrastructure to the European Advanced Translational Research Infrastructure in Medicine

Citovat

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ a Irena KOUTNÁ. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. Transplant Immunology. Amsterdam: Elsevier B.V., 2022, roč. 71, April, s. 1-13. ISSN 0966-3274. Dostupné z: https://dx.doi.org/10.1016/j.trim.2022.101539.

@article{1843917,
   author = {Ťapuchová, Ivana and Pytlik, Robert and Šimara, Pavel and Tesařová, Lenka and Koutná, Irena},
   article_location = {Amsterdam},
   article_number = {April},
   doi = {http://dx.doi.org/10.1016/j.trim.2022.101539},
   keywords = {Virus-specific T cells; Herpesviruses; Adoptive transfer; Cytomegalovirus; Resistance; Interferon gamma; Immunotherapy},
   language = {eng},
   issn = {0966-3274},
   journal = {Transplant Immunology},
   title = {Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells},
   url = {https://www.sciencedirect.com/science/article/pii/S0966327422000132},
   volume = {71},
   year = {2022}
}

TY  - JOUR
ID  - 1843917
AU  - Ťapuchová, Ivana - Pytlik, Robert - Šimara, Pavel - Tesařová, Lenka - Koutná, Irena
PY  - 2022
TI  - Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells
JF  - Transplant Immunology
VL  - 71
IS  - April
SP  - 1-13
EP  - 1-13
PB  - Elsevier B.V.
SN  - 09663274
KW  - Virus-specific T cells
KW  - Herpesviruses
KW  - Adoptive transfer
KW  - Cytomegalovirus
KW  - Resistance
KW  - Interferon gamma
KW  - Immunotherapy
UR  - https://www.sciencedirect.com/science/article/pii/S0966327422000132
N2  - Herpesviruses can either cause primary infection or may get reactivated after both hematopoietic cell and solid organ transplantations. In general, viral infections increase post-transplant morbidity and mortality. Prophylactic, preemptive, or therapeutically administered antiviral drugs may be associated with serious side effects and may induce viral resistance. Virus-specific T cells represent a valuable addition to antiviral treatment, with high rates of response and minimal side effects. Even low numbers of virus-specific T cells manufactured by direct selection methods can reconstitute virus-specific immunity after transplantation and control viral replication. Virus-specific T cells belong to the advanced therapy medicinal products, and their production is regulated by appropriate legislation; also, strict safety regulations are required to minimize their side effects.
ER  -

ŤAPUCHOVÁ, Ivana, Robert PYTLIK, Pavel ŠIMARA, Lenka TESAŘOVÁ a Irena KOUTNÁ. Cytomegalovirus and other herpesviruses after hematopoietic cell and solid organ transplantation: From antiviral drugs to virus-specific T cells. \textit{Transplant Immunology}. Amsterdam: Elsevier B.V., 2022, roč.~71, April, s.~1-13. ISSN~0966-3274. Dostupné z: https://dx.doi.org/10.1016/j.trim.2022.101539.

Podrobný výpis o publikaci